These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16033840)

  • 1. Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
    Scher HI; Morris MJ; Kelly WK; Schwartz LH; Heller G
    Clin Cancer Res; 2005 Jul; 11(14):5223-32. PubMed ID: 16033840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
    Scher HI; Halabi S; Tannock I; Morris M; Sternberg CN; Carducci MA; Eisenberger MA; Higano C; Bubley GJ; Dreicer R; Petrylak D; Kantoff P; Basch E; Kelly WK; Figg WD; Small EJ; Beer TM; Wilding G; Martin A; Hussain M;
    J Clin Oncol; 2008 Mar; 26(7):1148-59. PubMed ID: 18309951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
    Bubley GJ; Carducci M; Dahut W; Dawson N; Daliani D; Eisenberger M; Figg WD; Freidlin B; Halabi S; Hudes G; Hussain M; Kaplan R; Myers C; Oh W; Petrylak DP; Reed E; Roth B; Sartor O; Scher H; Simons J; Sinibaldi V; Small EJ; Smith MR; Trump DL; Wilding G
    J Clin Oncol; 1999 Nov; 17(11):3461-7. PubMed ID: 10550143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
    Scher HI; Eisenberger M; D'Amico AV; Halabi S; Small EJ; Morris M; Kattan MW; Roach M; Kantoff P; Pienta KJ; Carducci MA; Agus D; Slovin SF; Heller G; Kelly WK; Lange PH; Petrylak D; Berg W; Higano C; Wilding G; Moul JW; Partin AN; Logothetis C; Soule HR
    J Clin Oncol; 2004 Feb; 22(3):537-56. PubMed ID: 14752077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (18)F-Choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer.
    Kwee SA; Coel MN; Ly BH; Lim J
    Ann Nucl Med; 2009 Aug; 23(6):541-8. PubMed ID: 19529978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials.
    Dawson NA
    J Clin Oncol; 1998 Oct; 16(10):3398-405. PubMed ID: 9779719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
    Sonpavde G; Pond GR; Templeton AJ; Fandi A; Tombal B; Rosenthal M; Armstrong AJ; Petrylak DP
    Eur Urol; 2016 Jun; 69(6):980-3. PubMed ID: 26497922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
    Garcia JA; Hutson TE; Shepard D; Elson P; Dreicer R
    Cancer; 2011 Feb; 117(4):752-7. PubMed ID: 20922803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CT flare response of metastatic bone disease in prostate cancer.
    Messiou C; Cook G; Reid AH; Attard G; Dearnaley D; de Bono JS; de Souza NM
    Acta Radiol; 2011 Jun; 52(5):557-61. PubMed ID: 21498309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria.
    Velez EM; Desai B; Ji L; Quinn DI; Colletti PM; Jadvar H
    Theranostics; 2020; 10(7):3254-3262. PubMed ID: 32194866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease.
    Dreicer R; Garcia J; Hussain M; Rini B; Vogelzang N; Srinivas S; Somer B; Zhao YD; Kania M; Raghavan D
    Invest New Drugs; 2011 Dec; 29(6):1441-8. PubMed ID: 20369375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era.
    Bianco FJ
    Urol Oncol; 2008; 26(4):408-14. PubMed ID: 18593619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
    Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Berry D; Clarke N; Collette L; D'Amico A; Lourenco RA; Dignam J; Eisenberger M; James N; Fizazi K; Gillessen S; Loriot Y; Mottet N; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ;
    J Clin Oncol; 2020 Sep; 38(26):3032-3041. PubMed ID: 32552276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
    Liu G; Chen YH; Dipaola R; Carducci M; Wilding G
    Clin Genitourin Cancer; 2012 Jun; 10(2):99-105. PubMed ID: 22386239
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.